OmniAb rises on drug discovery deal with Lilly worth up to $370 million
BUZZ-OmniAb rises on drug discovery deal with Lilly worth up to $370 million Updates
** Shares of biotech firm OmniAb OABI.O rise 18% to $4, hitting its highest level since November 2024
** Co says it signed a global collaboration and license agreement with Eli Lilly LLY.N for a new ion channel drug discovery program
** Says it will receive an upfront payment and is eligible for up to $370 mln in research, development and commercial milestone payments
** Ion channels are proteins that help control signals in cells and are targets for treatments across several diseases
** OmniAb says the partnership will use its antibody discovery platform and ion channel screening expertise
** Agreement also includes tiered royalties on global net sales; therapeutic target and drug type were not disclosed
** Including session's move, stock up ~113% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on OmniAB
See all newsU.S. STOCKS ON THE MOVE - Nvidia, Gold miners, Nike
U.S. STOCKS ON THE MOVE - Sunrun, JetBlue Airways, Dell Technologies
OmniAb rises on drug discovery deal with Lilly worth up to $370 million
U.S. STOCKS ON THE MOVE - KBR, Vista Energy, Fulcrum Therapeutics
OmniAb rises on drug discovery deal with Lilly worth up to $370 mln